Supernus' Trokendi XR Faces Generic Threat from Zydus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 15, 5:45PM CDT
Supernus Pharmaceuticals, Inc. (SUPN) received a Paragraph IV notice from Zydus which is looking to get its generic version of Supernus' Trokendi XR approved in the U.S.
MNK: 83.19 (-1.14), ACT: 222.07 (+4.83), SUPN: 8.39 (+0.23), MYL: 48.77 (+1.39)
Mallinckrodt Gives FY15 Guidance Post Questcor Acquisition - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 15, 4:10PM CDT
Mallinckrodt plc (MNK) has issued its financial guidance for the fiscal year ending Sep 25, 2015 following the completion of the Questcor acquisition.
MNK: 83.19 (-1.14), ACT: 222.07 (+4.83), LGND: 48.86 (+2.58), MYL: 48.77 (+1.39)
Mallinckrodt expects fiscal 2015 adjusted EPS in the USD6.70 to USD7.20 range
M2 - Wed Oct 15, 6:05AM CDT
Biopharmaceutical company Mallinckrodt (NYSE:MNK) said on Tuesday that it expects its adjusted diluted earnings per share (EPS) in the USD6.70 to USD7.20 range for fiscal year ending 25 September 2015.
MNK: 83.19 (-1.14)
Mallinckrodt shares rise on earnings outlook
AP - Tue Oct 14, 9:07AM CDT
NEW YORK (AP) — Shares of Mallinckrodt PLC rose Tuesday after the health care products maker posted an earnings outlook for next year that beat Wall Street expectations.
MNK: 83.19 (-1.14), QCOR: 93.60 (+1.52)
Mallinckrodt plc Provides Fiscal Year 2015 Financial Guidance
Business Wire - Tue Oct 14, 6:00AM CDT
Mallinckrodt plc (NYSE: MNK), a leading global specialty biopharmaceutical company, today announced financial guidance for its fiscal year ending September 25, 2015.
MNK: 83.19 (-1.14)
Trade-Ideas: Mallinckrodt (MNK) Is Today's "Water-Logged And Getting Wetter" Stock
at The Street - Mon Oct 13, 9:59AM CDT
Trade-Ideas LLC identified Mallinckrodt (MNK) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate
MNK: 83.19 (-1.14)
10 Stocks Billionaire John Paulson Loves in 2014
at The Street - Mon Oct 13, 9:04AM CDT
Here's a look at 10 stocks that Paulson & Co. bought in the most recently reported quarter.
MNK: 83.19 (-1.14), AGN: 178.00 (+0.41), QCOR: 93.60 (+1.52), HSH: 62.96 (unch), SHPG: 178.46 (+7.97), COV: 85.50 (-0.36), DTV: 83.88 (+0.25), DG: 58.77 (+0.09), FDO: 76.37 (-0.16), CIE: 10.61 (+0.48)
AxoGen (AXGN) Shows Strength: Stock Up 15.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 13, 8:39AM CDT
AxoGen, Inc. (AXGN) was a big mover last session, as its shares rose over 15% on the day.
MNK: 83.19 (-1.14), ACT: 222.07 (+4.83), AXGN: 2.66 (-0.25), MYL: 48.77 (+1.39)
'Mad Money' Lightning Round: Buy Kimberly-Clark or Procter & Gamble
at The Street - Sat Oct 11, 5:00AM CDT
Cramer says FMC and Expedia are not done going lower and thinks of Organovo Holdings as a speculative stock.
MNK: 83.19 (-1.14), ONVO: 6.21 (+0.04), KMB: 105.04 (-0.37), EXPE: 75.08 (+0.98), FMC: 56.14 (+1.83), PG: 82.24 (-0.71)
Jim Cramer's Top Stock Picks: ISIS KMB PG MNK
at The Street - Sat Oct 11, 5:00AM CDT
Cramer sees better times ahead for Isis Pharmaceuticals and is a big fan of Kimberly-Clark.
MNK: 83.19 (-1.14), ISIS: 40.56 (+1.59), KMB: 105.04 (-0.37), PG: 82.24 (-0.71)
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - Fri Oct 10, 6:59PM CDT
From JPMorgan to General Electric, Cramer says he'll be all over earnings next week.
MNK: 83.19 (-1.14), GE: 24.25 (-0.03), HON: 86.39 (+1.28), C: 49.75 (+0.07), KMB: 105.04 (-0.37), MCHP: 39.19 (+1.46), FMC: 56.14 (+1.83), WFC: 48.13 (+0.28), CSX: 32.98 (unch), INTC: 30.85 (-0.42), NFLX: 361.70 (-86.89), ISIS: 40.56 (+1.59), JPM: 55.08 (-0.45), ONVO: 6.21 (+0.04), EXPE: 75.08 (+0.98), PG: 82.24 (-0.71), PPG: 181.83 (+1.33)
Impax Up, Set to Buy Tower Holdings & Lineage Therapeutics - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 10, 4:05PM CDT
Impax Laboratories Inc.'s (IPXL) signed a definitive agreement to acquire privately held Tower Holding and Lineage Therapeutics.
MNK: 83.19 (-1.14), IPXL: 27.00 (+0.26), ACT: 222.07 (+4.83), MYL: 48.77 (+1.39)
Impax Laboratories Inc. (IPXL) in Focus: Stock Rises 11.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 10, 8:32AM CDT
Impax Laboratories Inc. (IPXL) was a big mover last session, as the company saw its shares rise nearly 12% on the day.
MNK: 83.19 (-1.14), ACT: 222.07 (+4.83), MYL: 48.77 (+1.39)
Teva Starts Rolling Submission of its Pain Drug CEP-33237 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 09, 3:45PM CDT
Teva Pharmaceutical (TEVA) started a rolling submission of the NDA in the U.S. for CEP-33237.
MNK: 83.19 (-1.14), ACT: 222.07 (+4.83), MYL: 48.77 (+1.39), TEVA: 51.56 (+1.47)
Ligand Provides Better-than-Expected Q3 Earnings Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 09, 3:10PM CDT
Ligand Pharmaceuticals Incorporated (LGND) is expecting its third quarter 2014 adjusted earnings per share to be between 33 and 37 cents per share.
MNK: 83.19 (-1.14), ACT: 222.07 (+4.83), LGND: 48.86 (+2.58), MYL: 48.77 (+1.39)
Teva to Concentrate on Core Specialty Therapeutics - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 07, 5:09PM CDT
Teva Pharmaceutical (TEVA) announced that it will be primarily focusing on its core therapeutic areas.
MNK: 83.19 (-1.14), ACT: 222.07 (+4.83), TEVA: 51.56 (+1.47), GSK: 42.88 (-0.25)
Actavis in Acquisition Mode, Durata Deal to Boost Portfolio - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 07, 4:42PM CDT
Actavis (ACT) will expand its infectious disease portfolio through the Durata (DRTX) acquisition.
DRTX: 23.60 (-0.03), MNK: 83.19 (-1.14), ACT: 222.07 (+4.83), SUPN: 8.39 (+0.23)
Eli Lilly Stops Developing Tabalumab Due to Efficacy Issues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 07, 4:30PM CDT
Eli Lilly and Company (LLY) will discontinue tabalumab's development due to insufficient efficacy results in the phase III ILLUMINATE program.
MNK: 83.19 (-1.14), ACT: 222.07 (+4.83), LGND: 48.86 (+2.58), LLY: 61.90 (-0.97)
AbbVie's Humira Label Expanded in U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 07, 4:05PM CDT
AbbVie Inc.'s (ABBV) Humira gained FDA approval for moderately-to-severely active polyarticular juvenile idiopathic arthritis in patients aged less than or equal to 2 years.
MNK: 83.19 (-1.14), ACT: 222.07 (+4.83), LGND: 48.86 (+2.58), ABBV: 52.90 (-1.73)
Progenics Gets $40M Milestone on FDA Approval of Relistor - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 07, 4:05PM CDT
Progenics Pharmaceuticals, Inc. (PGNX) received a $40 million milestone payment from Salix Pharmaceuticals, Inc. (SLXP) on the U.S. approval of Relistor.
MNK: 83.19 (-1.14), PGNX: 4.85 (+0.21), ACT: 222.07 (+4.83), SLXP: 137.38 (+4.96)